The adverse effects of PD-1 blockers on the CNS observed in cancer patients could occur through their effects on an enzyme that activates microglia. Pharmacological inhibition of the enzyme in mice reduced microglial activation and cognitive deficit without altering the antitumor capacity of the immunotherapy. Read More
KYV-201 is an investigational allogeneic anti-CD19 CAR T-cell therapy candidate being developed by Kyverna Therapeutics Inc. for the treatment of B-cell-driven autoimmune diseases. Read More
Alivexis Inc. has entered into a research collaboration agreement with Astellas Pharma Inc. to identify small-molecule compounds for a new drug target selected by Astellas. Read More
B-cell lymphoma 6 (BCL6) is up-regulated in several B-cell malignancies where it acts as a transcription factor activity mediator to induce and maintain lymphomagenesis. Read More
The development of resistance and relapse during the blast phase of chronic myeloid leukemia poses a challenge in the management of this pathology, with half of the cases accounting for FLT3 pathway activation that, in turn, contributes to tyrosine kinase inhibitor resistance. Read More
Systemic sclerosis is an autoimmune disorder characterized by inflammation, vasculopathy and fibrosis, mainly affecting internal organs and the skin. There is still a lack of therapies for SSc-induced skin fibrosis. Read More
Daegu-Gyeongbuk Medical Innovation Foundation has disclosed estrogen receptor α (ER-α; ESR1) antagonists reported to be useful for the treatment of cancer. Read More
Revir Therapeutics Inc. has announced the achievement of a milestone under its ongoing collaboration with Asieris Pharmaceuticals Co. Ltd. to develop treatments for cancers using a novel target. Read More
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized cyclin-dependent kinase 8 (CDK8) and/or CDK19 inhibitors reported to be useful for the treatment of cancer. Read More
Pic Therapeutics Inc. has identified eukaryotic translation initiation factor 4E (eiF4E) inhibitors reported to be useful for the treatment of cancer. Read More
Angiogenesis plays a crucial role in multiple myeloma and its prognosis, with the success of antiangiogenic therapies being limited. Exosomes mediate cell-to-cell cross talk during the progression of cancer by transporting their molecular cargo, which include long non-coding RNAs (lncRNAs); their role in multiple myeloma was investigated. Read More
Lhotse Bio Inc. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer, fibrosis, inflammatory disorders, multiple sclerosis, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly nonalcoholic fatty liver disease [NAFLD]), osteoporosis, SARS-CoV-2 infection (COVID-19) and transplant rejection. Read More
Researchers from Philochem AG recently reported the discovered OncoFAP, a high-affinity small organic ligand of fibroblast activation protein (FAP) that has shown rapid accumulation in tumors and low uptake in healthy tissues in preclinical models. Read More
